Literature DB >> 14678966

Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors.

Tsuneo Ikenoue1, Yohko Hikiba, Fumihiko Kanai, Yasuo Tanaka, Jun Imamura, Takaaki Imamura, Miki Ohta, Hideaki Ijichi, Keisuke Tateishi, Takayuki Kawakami, Jun Aragaki, Masayuki Matsumura, Takao Kawabe, Masao Omata.   

Abstract

Mutations in the B-Raf gene have been reported in a number of human cancers, including colorectal carcinoma. More than 80% of the B-Raf mutations were V599E. Although other mutations have been reported, their functional consequences were unclear. Here, we examined the effect of colon tumor-associated B-Raf mutations within the kinase activation segment, including V599E, on extracellular signal-regulated kinase (Erk) and nuclear factor kappaB (NFkappaB) signaling, and on the transformation of NIH3T3 fibroblasts. Among the six mutations examined, only the B-Raf V599E and K600E mutations greatly increased Erk and NFkappaB signaling, and the transformation of NIH3T3 cells. The B-Raf F594L mutation moderately elevated Erk signaling and NIH3T3 transformation, but did not significantly increase NFkappaB signaling. Although the basal kinase activity of the B-Raf T598I mutant was comparable with that of wild-type, its oncogenic Ras-induced kinase activity was decreased to 60% of wild-type activity. The B-Raf D593V and G595R mutants showed severely reduced kinase activity and affected neither NFkappaB signaling nor NIH3T3 transforming activity. These results suggest that the B-Raf activation segment mutations other than V599E reported in colorectal tumors do not necessarily contribute to carcinogenesis by increasing kinase and transforming activities.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14678966

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  61 in total

1.  Drug discovery: inhibitors that activate.

Authors:  Karen Cichowski; Pasi A Jänne
Journal:  Nature       Date:  2010-03-18       Impact factor: 49.962

2.  Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib.

Authors:  Banibrata Sen; Shaohua Peng; Ximing Tang; Heidi S Erickson; Hector Galindo; Tuhina Mazumdar; David J Stewart; Ignacio Wistuba; Faye M Johnson
Journal:  Sci Transl Med       Date:  2012-05-30       Impact factor: 17.956

Review 3.  Histology-agnostic drug development - considering issues beyond the tissue.

Authors:  Roberto Carmagnani Pestana; Shiraj Sen; Brian P Hobbs; David S Hong
Journal:  Nat Rev Clin Oncol       Date:  2020-06-11       Impact factor: 66.675

4.  Identification of a novel family of BRAF(V600E) inhibitors.

Authors:  Jie Qin; Peng Xie; Christian Ventocilla; Guoqiang Zhou; Adina Vultur; Quan Chen; Qin Liu; Meenhard Herlyn; Jeffrey Winkler; Ronen Marmorstein
Journal:  J Med Chem       Date:  2012-05-18       Impact factor: 7.446

Review 5.  Emerging roles for the non-canonical IKKs in cancer.

Authors:  R R Shen; W C Hahn
Journal:  Oncogene       Date:  2010-11-01       Impact factor: 9.867

6.  Targeting mutant (V600E) B-Raf in melanoma interrupts immunoediting of leukocyte functions and melanoma extravasation.

Authors:  Shile Liang; Arati Sharma; Hsin-Hsin Peng; Gavin Robertson; Cheng Dong
Journal:  Cancer Res       Date:  2007-06-15       Impact factor: 12.701

Review 7.  Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.

Authors:  Matthew Dankner; April A N Rose; Shivshankari Rajkumar; Peter M Siegel; Ian R Watson
Journal:  Oncogene       Date:  2018-03-15       Impact factor: 9.867

8.  Chemically Linked Vemurafenib Inhibitors Promote an Inactive BRAFV600E Conformation.

Authors:  Michael Grasso; Michelle A Estrada; Christian Ventocilla; Minu Samanta; Jasna Maksimoska; Jessie Villanueva; Jeffrey D Winkler; Ronen Marmorstein
Journal:  ACS Chem Biol       Date:  2016-09-06       Impact factor: 5.100

9.  Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.

Authors:  Muling Mao; Feng Tian; John M Mariadason; Chun C Tsao; Robert Lemos; Farshid Dayyani; Y N Vashisht Gopal; Zhi-Qin Jiang; Ignacio I Wistuba; Xi M Tang; William G Bornman; Gideon Bollag; Gordon B Mills; Garth Powis; Jayesh Desai; Gary E Gallick; Michael A Davies; Scott Kopetz
Journal:  Clin Cancer Res       Date:  2012-12-18       Impact factor: 12.531

Review 10.  Molecular pathogenesis and mechanisms of thyroid cancer.

Authors:  Mingzhao Xing
Journal:  Nat Rev Cancer       Date:  2013-03       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.